Korea Mulls Moves To Aid Smaller Pharma Firms
This article was originally published in PharmAsia News
South Korea's Ministry of Food and Drug Safety has suggested steps to help small- and medium-sized pharma firms in the country overcome difficulties stemming from increased investment costs, lower drug prices and the MERS outbreak. The measures include forming a consultative group to discuss obstacles and mutual cooperation at the development and other stages.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.